Serina Therapeutics, Inc.
Income Statement
| Line Item | FY2017 |
|---|---|
| Revenue | $1.4M |
| Cost of Revenue | $168.0K |
| Gross Profit | $1.2M |
| Gross Margin | 88.0% |
| Operating Expenses | |
| Research & Development | $5.8M |
| SG&A Expense | $3.9M |
| Operating Income | $-6.7M |
| Operating Margin | -474.6% |
| Interest Expense | — |
| Pretax Income | — |
| Income Tax Expense | — |
| Net Income | $-6.6M |
| Net Margin | -468.7% |
| EPS (Basic) | $0.00 |
| EPS (Diluted) | $0.00 |
| Shares Outstanding (Basic) | 229.94B |
| Shares Outstanding (Diluted) | 229.94B |
| Dividends Per Share | — |